Alpha Life Sciences

Alpha Life Sciences, founded in 2020 and based in China, applies generative AI and advanced computer science to clinical research documentation. The company automates medical writing and regulatory documentation across the full drug development lifecycle, serving pharmaceutical companies, biotechnology firms and contract research organisations (CROs). Its founders are senior technology and product experts previously at Google and Verily China.

The firm's principal product is AuroraPrime, a GenAI-powered SaaS platform that generates medical and regulatory documents using AI agents designed to work with regulatory logic, data structures and version control. The platform operates within FDA 21 CFR Part 11, HIPAA, GDPR, SOC 2 Type II, ISO 9001 and ISO 27001 frameworks, reflecting an emphasis on regulatory integrity and compliance technology.

Technical work at the company spans generative AI, AI agents, natural language generation, life sciences informatics, SaaS platform engineering and regulatory compliance. Alpha Life Sciences participates in the Microsoft Pegasus Program, Google for Startups, Johnson & Johnson Innovation JLABS and the NVIDIA Inception Program. The company's stated mission is to accelerate drug development and reduce time-to-market through intelligent digitalisation of clinical research documentation.